
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/299987/publications.pdf Version: 2024-02-01



DED C. FADIID

#	Article	IF	CITATIONS
1	Perceived food intolerance in subjects with irritable bowel syndrome – etiology, prevalence and consequences. European Journal of Clinical Nutrition, 2006, 60, 667-672.	1.3	315
2	Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications. Alimentary Pharmacology and Therapeutics, 2004, 20, 1195-1203.	1.9	134
3	Prevalence, comorbidity and impact of irritable bowel syndrome in Norway. Scandinavian Journal of Gastroenterology, 2006, 41, 650-656.	0.6	115
4	Lactose malabsorption in a population with irritable bowel syndrome: prevalence and symptoms. A caseâ€control study. Scandinavian Journal of Gastroenterology, 2004, 39, 645-649.	0.6	104
5	Mesalazine Suppositories versus Hydrocortisone Foam in Patients with Distal Ulcerative Colitis:A Comparison of the Efficacy and Practicality of Two Topical Treatment Regimens. Scandinavian Journal of Gastroenterology, 1995, 30, 164-170.	0.6	88
6	A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterology, 2010, 10, 16.	0.8	80
7	Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome?. BMC Gastroenterology, 2016, 16, 51.	0.8	80
8	Mesalazine 4 g Daily Given as Prolonged-Release Granules Twice Daily and Four Times Daily Is at Least as Effective as Prolonged-Release Tablets Four Times Daily in Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2001, 7, 237-242.	0.9	62
9	The Relationships among Tryptophan, Kynurenine, Indoleamine 2,3-Dioxygenase, Depression, and Neuropsychological Performance. Frontiers in Psychology, 2017, 8, 1561.	1.1	58
10	Patients with Functional Dyspepsia Responding to Omeprazole Have a Characteristic Gastro-oesophageal Reflux Pattern. Scandinavian Journal of Gastroenterology, 1999, 34, 575-579.	0.6	56
11	Differences in medication knowledge and risk of errors between graduating nursing students and working registered nurses: comparative study. BMC Health Services Research, 2014, 14, 580.	0.9	55
12	Diagnosing irritable bowel syndrome: poor agreement between general practitioners and the Rome II criteria. Scandinavian Journal of Gastroenterology, 2004, 39, 448-453.	0.6	53
13	Constipation and diarrhoea - common adverse drug reactions? A cross sectional study in the general population. BMC Clinical Pharmacology, 2011, 11, 2.	2.5	52
14	Medication knowledge, certainty, and risk of errors in health care: a cross-sectional study. BMC Health Services Research, 2011, 11, 175.	0.9	52
15	A comparison of diagnostic tests for lactose malabsorption - which one is the best?. BMC Gastroenterology, 2009, 9, 82.	0.8	49
16	The Symptomatic Effect of Cisapride in Patients with Irritable Bowel Syndrome and Constipation. Scandinavian Journal of Gastroenterology, 1998, 33, 128-131.	0.6	47
17	Vitamin B6 deficiency and diseases in elderly people – a study in nursing homes. BMC Geriatrics, 2013, 13, 13.	1.1	46
18	The association between patient safety culture and burnout and sense of coherence: A cross-sectional study in restructured and not restructured intensive care units. Intensive and Critical Care Nursing, 2016, 36, 26-34.	1.4	46

#	Article	IF	CITATIONS
19	Drugs and Constipation in Elderly in Nursing Homes: What Is the Relation?. Gastroenterology Research and Practice, 2012, 2012, 1-7.	0.7	45
20	How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice. BMC Gastroenterology, 2010, 10, 31.	0.8	41
21	Probiotics, Symptoms, and Gut Microbiota: What Are the Relations? A Randomized Controlled Trial in Subjects with Irritable Bowel Syndrome. Gastroenterology Research and Practice, 2012, 2012, 1-6.	0.7	40
22	Changes in Faecal Short-Chain Fatty Acids after Weight-Loss Interventions in Subjects with Morbid Obesity. Nutrients, 2020, 12, 802.	1.7	40
23	lgG and IgG4 antibodies in subjects with irritable bowel syndrome: a case control study in the general population. BMC Gastroenterology, 2012, 12, 166.	0.8	39
24	Burnout in health-care professionals during reorganizations and downsizing. A cohort study in nurses. BMC Nursing, 2010, 9, 8.	0.9	37
25	Low intake of vitamin B6 is associated with irritable bowel syndrome symptoms. Nutrition Research, 2011, 31, 356-361.	1.3	35
26	Diet in subjects with irritable bowel syndrome: A cross-sectional study in the general population. BMC Gastroenterology, 2012, 12, 61.	0.8	34
27	Are measurements of patient safety culture and adverse events valid and reliable? Results from a cross sectional study. BMC Health Services Research, 2015, 15, 186.	0.9	32
28	Ranitidine for Non-Ulcer Dyspepsia: A Clinical Study of the Symptomatic Effect of Ranitidine and a Classification and Characterization of the Responders to Treatment. Scandinavian Journal of Gastroenterology, 1991, 26, 1209-1216.	0.6	30
29	Patients with depression display cytokine levels in serum and cerebrospinal fluid similar to patients with diffuse neurological symptoms without a defined diagnosis. Neuropsychiatric Disease and Treatment, 2016, 12, 817.	1.0	28
30	Prevalence and predictors of irritable bowel syndrome in patients with morbid obesity: a cross-sectional study. BMC Obesity, 2017, 4, 22.	3.1	28
31	Predictors of health-related quality of life in patients with irritable bowel syndrome. A cross-sectional study in Norway. Health and Quality of Life Outcomes, 2015, 13, 113.	1.0	27
32	A Conservative Weight Loss Intervention Relieves Bowel Symptoms in Morbidly Obese Subjects with Irritable Bowel Syndrome: A Prospective Cohort Study. Journal of Obesity, 2018, 2018, 1-9.	1.1	26
33	Low-Dose Antacids or Cimetidine for Duodenal Ulcer?. Gastroenterology, 1988, 95, 1465-1469.	0.6	25
34	Improvement of drug dose calculations by classroom teaching or e-learning: a randomised controlled trial in nurses. BMJ Open, 2014, 4, e006025.	0.8	24
35	Comparison of Three Triple Regimens with Omeprazole or Ranitidine Bismuth Citrate for Helicobacter pylori Eradication. Scandinavian Journal of Gastroenterology, 2002, 37, 1374-1379.	0.6	23
36	Changes in serum zonulin in individuals with morbid obesity after weight-loss interventions: a prospective cohort study. BMC Endocrine Disorders, 2020, 20, 108.	0.9	23

#	Article	IF	CITATIONS
37	Long-Term Treatment with 300 Mg Ranitidine Once Daily after Dilatation of Peptic Oesophageal Strictures. Scandinavian Journal of Gastroenterology, 1992, 27, 594-598.	0.6	22
38	Are Frequent Short Gastro-Oesophageal Reflux Episodes the Cause of Symptoms in Patients with Non-Ulcer Dyspepsia Responding to Treatment with Ranitidine?. Scandinavian Journal of Gastroenterology, 1995, 30, 829-832.	0.6	22
39	The Rate of Healing of Duodenal Ulcers during Omeprazole Treatment. Scandinavian Journal of Gastroenterology, 1985, 20, 691-695.	0.6	21
40	The Multi-Crossover Model for Classifying Patients as Responders to a Given Treatment. Scandinavian Journal of Gastroenterology, 1991, 26, 763-770.	0.6	18
41	Effectiveness of laxatives in elderly - a cross sectional study in nursing homes. BMC Geriatrics, 2011, 11, 76.	1.1	18
42	Abdominal complaints in general practice Diagnoses and characteristics of patients. Scandinavian Journal of Primary Health Care, 2004, 22, 157-162.	0.6	16
43	Are Nonnutritive Sweeteners Obesogenic? Associations between Diet, Faecal Microbiota, and Short-Chain Fatty Acids in Morbidly Obese Subjects. Journal of Obesity, 2019, 2019, 1-8.	1.1	16
44	Sphincter of Oddi Dysfunction: Dynamic Cholescintigraphy and Endoscopic Retrograde Cholangiopancreatography with Papillotomy in Diagnosis, Treatment, and Follow-up Study. Scandinavian Journal of Gastroenterology, 1989, 24, 956-960.	0.6	15
45	Does Short-term Treatment With Proton Pump Inhibitors Cause Rebound Aggravation of Symptoms?. Journal of Clinical Gastroenterology, 2001, 33, 206-209.	1.1	15
46	Changes in gastrointestinal symptoms and food tolerance 6Âmonths following weight loss surgery: associations with dietary changes, weight loss and the surgical procedure. BMC Obesity, 2018, 5, 29.	3.1	15
47	The value of a general therapeutic approach in subjects with irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2005, 21, 21-27.	1.9	14
48	Vitamin B6 in plasma – sample stability and the reference limits. Scandinavian Journal of Clinical and Laboratory Investigation, 2013, 73, 476-479.	0.6	14
49	Changes in patient safety culture after restructuring of intensive care units: Two cross-sectional studies. Intensive and Critical Care Nursing, 2016, 32, 58-65.	1.4	14
50	Effects of a fall prevention program in elderly: a pragmatic observational study in two orthopedic departments. Clinical Interventions in Aging, 2019, Volume 14, 145-154.	1.3	13
51	Zaltidine: An Effective but Hepatotoxic H2-Receptor Antagonist. Scandinavian Journal of Gastroenterology, 1988, 23, 655-658.	0.6	12
52	Duodenal Ulcer Treated with Omeprazole: Healing and Relapse Rates. Scandinavian Journal of Gastroenterology, 1989, 24, 1107-1112.	0.6	11
53	Patient education in gastro-oesophageal reflux disease: a randomized controlled trial. European Journal of Gastroenterology and Hepatology, 2007, 19, 1104-1110.	0.8	11
54	Intake of non-nutritive sweeteners is associated with an unhealthy lifestyle: a cross-sectional study in subjects with morbid obesity. BMC Obesity, 2017, 4, 41.	3.1	11

#	Article	IF	CITATIONS
55	Evaluation of a faecal dysbiosis test for irritable bowel syndrome in subjects with and without obesity. Scandinavian Journal of Clinical and Laboratory Investigation, 2018, 78, 109-113.	0.6	11
56	Irritable bowel syndrome-like symptoms and health related quality of life two years after Roux-en-Y gastric bypass - a prospective cohort study. BMC Gastroenterology, 2019, 19, 204.	0.8	11
57	APOE – a genetic marker of comorbidity in subjects with morbid obesity. BMC Medical Genetics, 2020, 21, 146.	2.1	11
58	Disease knowledge after an educational program in patients with GERD – a randomized controlled trial. BMC Health Services Research, 2008, 8, 236.	0.9	10
59	How useful are the Rome II criteria for identification of upper gastrointestinal disorders in general practice?. Scandinavian Journal of Gastroenterology, 2005, 40, 1284-1289.	0.6	9
60	What causes treatment failure - the patient, primary care, secondary care or inadequate interaction in the health services?. BMC Health Services Research, 2011, 11, 111.	0.9	9
61	Cognitive Functions and Depression in Patients with Irritable Bowel Syndrome. Gastroenterology Research and Practice, 2015, 2015, 1-9.	0.7	9
62	Anti-Saccharomyces cerevisiae antibodies (ASCA) are associated with body fat mass and systemic inflammation, but not with dietary yeast consumption: a cross-sectional study. BMC Obesity, 2017, 4, 28.	3.1	9
63	Changes in C-reactive protein, neopterin and lactoferrin differ after conservative and surgical weight loss in individuals with morbid obesity. Scientific Reports, 2019, 9, 17695.	1.6	9
64	Effect of Cisapride on Symptoms and Biliary D in Patients with Postcholecystectomy Syndrome. Scandinavian Journal of Gastroenterology, 1991, 26, 945-950.	0.6	8
65	Digestive symptoms and their psychosocial impact: Validation of a questionnaire. Scandinavian Journal of Gastroenterology, 2006, 41, 1019-1027.	0.6	8
66	Functional Bowel Disorders Are Associated with a Central Immune Activation. Gastroenterology Research and Practice, 2017, 2017, 1-9.	0.7	8
67	Separating "good―from "bad―faecal dysbiosis – evidence from two cross-sectional studies. BMC Obesity, 2018, 5, 30.	3.1	8
68	The Effect of Helicobacter pylori Retreatment With Ranitidine Bismuth Citrate, Clarithromycin, and Metronidazole Depends on the First-Line Therapy. Journal of Clinical Gastroenterology, 2002, 35, 379-382.	1.1	7
69	Idiopathic Hypoparathyroidism and Hyperthyroidism. Acta Medica Scandinavica, 1977, 202, 261-264.	0.0	7
70	Managing the Uninvestigated Dyspeptic Patient. Scandinavian Journal of Gastroenterology, 1999, 34, 1169-1170.	0.6	6
71	The effect of ApoE e4 on blood pressure in patients with and without depression. Neuropsychiatric Disease and Treatment, 2016, 12, 1365.	1.0	6
72	APOE Polymorphism and Endocrine Functions in Subjects with Morbid Obesity Undergoing Bariatric Surgery. Genes, 2022, 13, 222.	1.0	6

#	Article	IF	CITATIONS
73	Are the Results of a Combined Behavioural and Surgical Treatment of Morbid Obesity Satisfactory and Predictable?. Nutrients, 2020, 12, 1997.	1.7	5
74	Collaboration by Use of the Internet Yields Data of High Quality and Detects Non-uniform Management of Patients with Helicobacter pylori Infection. Scandinavian Journal of Gastroenterology, 2002, 37, 1466-1470.	0.6	4
75	Is perceived intolerance to milk and wheat associated with the corresponding IgG and IgA food antibodies? A cross sectional study in subjects with morbid obesity and gastrointestinal symptoms. BMC Gastroenterology, 2018, 18, 22.	0.8	4
76	Are Faecal Microbiota Analyses on Species-Level Suitable Clinical Biomarkers? A Pilot Study in Subjects with Morbid Obesity. Microorganisms, 2021, 9, 664.	1.6	4
77	Circulating Lipoproteins in Subjects with Morbid Obesity Undergoing Bariatric Surgery with Gastric Bypass or Sleeve Gastrectomy. Nutrients, 2022, 14, 2381.	1.7	4
78	Alternative vs. conventional treatment given on-demand for gastroesophageal reflux disease: a randomised controlled trial. BMC Complementary and Alternative Medicine, 2009, 9, 3.	3.7	3
79	The Culture of Incident Reporting and Feedback: A Cross-Sectional Study in a Hospital Setting. Open Journal of Nursing, 2015, 05, 1042-1052.	0.2	3
80	The Peripheral Kynurenine Pathway and Psychosomatic Comorbidity in Subjects with Morbid Obesity Undergoing Bariatric Surgery. Applied Sciences (Switzerland), 2022, 12, 2648.	1.3	3
81	Rate of Healing of Benign Gastric Ulcer During Treatment with Omeprazole. Scandinavian Journal of Gastroenterology, 1986, 21, 180-180.	0.6	2
82	Functional Dyspepsia and Gastric Acid: Any Relation?. Scandinavian Journal of Gastroenterology, 2002, 37, 1349-1350.	0.6	2
83	Questions about mesalazine and the irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2011, 34, 1036-1037.	1.9	2
84	Irritable Bowel Syndrome. Gastroenterology Research and Practice, 2012, 2012, 1-2.	0.7	2
85	Faecal Microbial Markers and Psychobiological Disorders in Subjects with Morbid Obesity. A Cross-Sectional Study. Behavioral Sciences (Basel, Switzerland), 2018, 8, 89.	1.0	2
86	Tegaserod—merely a laxative?. Scandinavian Journal of Gastroenterology, 2004, 39, 404-405.	0.6	1
87	Does short term treatment with high dose lansoprazole cause rebound aggravation of symptoms?. Gastroenterology, 2000, 118, A16.	0.6	Ο
88	Health anxiety predicts persisting complaints in IBS patients. Gastroenterology, 2003, 124, A529-A530.	0.6	0
89	Milk related disorders. A comparison between patients with IBS and healthy volunteers. Gastroenterology, 2003, 124, A260.	0.6	0
90	In response to Montes and Monge. Scandinavian Journal of Gastroenterology, 2004, 39, 1033-1033.	0.6	0

#	Article	IF	CITATIONS
91	Abdominal complaints in general practice: Diagnoses and characteristics of patients. Scandinavian Journal of Primary Health Care, 2005, 23, 126-127.	0.6	0